bortezomibhttp://www.unboundmedicine.com/medline/ebm/research/bortezomibUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.http://www.unboundmedicine.com/medline/ebm/record/19894220/full_citation/proteasome_inhibition_with_bortezomib_suppresses_growth_and_induces_apoptosis_in_osteosarcoma_Shapovalov Y, Benavidez D, Zuch D, et al. 
proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. [JOURNAL ARTICLE]
Int J Cancer 2009 Nov 5.
Abstract | Full CitationAmyloid in bone marrow smears of patients affected by multiple myeloma.http://www.unboundmedicine.com/medline/ebm/record/19894050/full_citation/Amyloid_in_bone_marrow_smears_of_patients_affected_by_multiple_myeloma_Petruzziello F, Zeppa P, Catalano L, et al. 
Amyloid in bone marrow smears of patients affected by multiple myeloma. [JOURNAL ARTICLE]
Ann Hematol 2009 Nov 6.
Abstract | Full Citation | Find Related Articles TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.http://www.unboundmedicine.com/medline/ebm/record/19890373/full_citation/TNF_alpha_converting_enzyme__TACE/ADAM17__dependent_loss_of_CD30_induced_by_proteasome_inhibition_through_reactive_oxygen_species_Vahdat AM, Reiners KS, Simhadri VL, et al. 
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. [JOURNAL ARTICLE]
Leukemia 2009 Nov 5.
Abstract | Full Citation | Find Related Articles Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.http://www.unboundmedicine.com/medline/ebm/record/19890210/full_citation/Deciphering_antibody_mediated_rejection:_new_insights_into_mechanisms_and_treatment_Stegall MD, Gloor JM 
Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. [JOURNAL ARTICLE]
Curr Opin Organ Transplant 2009 Nov 3.
Abstract | Full Citation | Find Related Articles Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.http://www.unboundmedicine.com/medline/ebm/record/19889456/full_citation/Clonal_evolution_at_leukemic_relapse_of_multiple_myeloma__secondary_plasma_cell_leukemia__responding_to_re_treatment_with_bortezomib_based_therapy__A_case_record_Bernardeschi P, Pirrotta MT, Montenora I, et al. 
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record. [LETTER]
Leuk Res 2009 Nov 2.
Full Citation | Find Related Articles Multiple Myeloma, Painful Neuropathy, Acupuncture?http://www.unboundmedicine.com/medline/ebm/record/19887992/full_citation/Multiple_Myeloma_Painful_Neuropathy_AcupunctureZhou Y, Garcia MK, Chang DZ, et al. 
Multiple Myeloma, Painful Neuropathy, Acupuncture? [JOURNAL ARTICLE]
Am J Clin Oncol 2009 Jun; 32(3):319-325.
Abstract | Full CitationRole of ATF4 in regulation of autophagy and resistance to drugs and hypoxia.http://www.unboundmedicine.com/medline/ebm/record/19887912/full_citation/Role_of_ATF4_in_regulation_of_autophagy_and_resistance_to_drugs_and_hypoxia_Rzymski T, Milani M, Singleton DC, et al. 
Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. [JOURNAL ARTICLE]
Cell Cycle 2009 Dec 15; 8(23)
Abstract | Full Citation | Find Related Articles Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma.http://www.unboundmedicine.com/medline/ebm/record/19887870/full_citation/Multiple_bulky_cutaneous_plasmacytomas_with_CNS_relapse_without_bone_marrow_involvement_during_the_course_of_a_lambda_light_chain_myeloma_Serefhanoglu S, Haznedaroglu IC, Goker H, et al. 
Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. [Journal Article]
Onkologie 2009 Nov; 32(11):662-4.
Abstract | Full Citation | Find Related Articles Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.http://www.unboundmedicine.com/medline/ebm/record/19887551/full_citation/Characterization_of_caspase_dependent_and_caspase_independent_deaths_in_glioblastoma_cells_treated_with_inhibitors_of_the_ubiquitin_proteasome_system_Foti C, Florean C, Pezzutto A, et al. 
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Nov 3.
Abstract | Full Citation | Find Related Articles Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroupe Francophone du Myelome (IFM).http://www.unboundmedicine.com/medline/ebm/record/19884643/full_citation/Bortezomib_and_high_dose_melphalan_as_conditioning_regimen_before_autologous_stem_cell_transplantation_in_patients_with_de_novo_multiple_myeloma:_a_phase_II_study_of_the_Intergroupe_Francophone_du_Myelome__IFM__Roussel M, Moreau P, Huynh A, et al. 
Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroupe Francophone du Myelome (IFM). [JOURNAL ARTICLE]
Blood 2009 Nov 2.
Abstract | Full Citation | Publisher Full Text | Find Related Articles